Oxurion Past Earnings Performance
Past criteria checks 0/6
Oxurion has been growing earnings at an average annual rate of 20.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 50.1% per year.
Key information
20.1%
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -50.1% |
| Return on equity | n/a |
| Net Margin | -13,539.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Oxurion makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -11 | 3 | 6 |
| 31 Mar 24 | 0 | -15 | 3 | 8 |
| 31 Dec 23 | 0 | -19 | 4 | 10 |
| 30 Sep 23 | 0 | -23 | 4 | 11 |
| 30 Jun 23 | 1 | -28 | 5 | 12 |
| 31 Mar 23 | 1 | -30 | 6 | 14 |
| 31 Dec 22 | 1 | -32 | 7 | 16 |
| 30 Sep 22 | 1 | -30 | 8 | 18 |
| 30 Jun 22 | 1 | -28 | 8 | 19 |
| 31 Mar 22 | 1 | -28 | 8 | 20 |
| 31 Dec 21 | 1 | -29 | 8 | 21 |
| 30 Sep 21 | 1 | -30 | 9 | 22 |
| 30 Jun 21 | 1 | -31 | 9 | 23 |
| 31 Mar 21 | 2 | -29 | 9 | 23 |
| 31 Dec 20 | 2 | -28 | 9 | 22 |
| 30 Sep 20 | 3 | -30 | 10 | 23 |
| 30 Jun 20 | 3 | -32 | 11 | 24 |
| 31 Mar 20 | 4 | -42 | 12 | 25 |
| 31 Dec 19 | 4 | -52 | 13 | 26 |
| 30 Sep 19 | 4 | -54 | 14 | 27 |
| 30 Jun 19 | 3 | -57 | 14 | 28 |
| 31 Mar 19 | 4 | -48 | 13 | 29 |
| 31 Dec 18 | 5 | -38 | 13 | 30 |
| 30 Sep 18 | 6 | -8 | 12 | 28 |
| 30 Jun 18 | 7 | 23 | 11 | 26 |
| 31 Mar 18 | 6 | 23 | 11 | 25 |
| 31 Dec 17 | 6 | 23 | 10 | 23 |
| 30 Sep 17 | 6 | -19 | 10 | 23 |
| 30 Jun 17 | 6 | -61 | 11 | 23 |
| 31 Mar 17 | 6 | -60 | 11 | 24 |
| 31 Dec 16 | 7 | -60 | 11 | 25 |
| 30 Sep 16 | 8 | -47 | 14 | 24 |
| 30 Jun 16 | 9 | -34 | 17 | 23 |
| 31 Mar 16 | 10 | -36 | 21 | 22 |
| 31 Dec 15 | 11 | -38 | 26 | 21 |
| 30 Sep 15 | 12 | -42 | 30 | 21 |
| 30 Jun 15 | 13 | -46 | 34 | 21 |
| 31 Mar 15 | 13 | -49 | 37 | 22 |
| 31 Dec 14 | 14 | -51 | 39 | 23 |
| 30 Sep 14 | 15 | -52 | 40 | 24 |
| 30 Jun 14 | 17 | -52 | 41 | 26 |
| 31 Mar 14 | 65 | -13 | 45 | 29 |
| 31 Dec 13 | 113 | 26 | 49 | 32 |
Quality Earnings: TG40 is currently unprofitable.
Growing Profit Margin: TG40 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TG40 is unprofitable, but has reduced losses over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare TG40's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TG40 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: TG40's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.